The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.
Age of ≥20*
Provided written consent to participate in the study *If the patient is 90 years of age or older and cognitive decline is considered necessary, Mini-Cog should be used to confirm that its score is not less than 3.
eGFR <20 mL/min/1.73m2 at the time of admission
Already taking an SGLT2i within 3 months prior to hospitalization
Type 1 diabetes mellitus
Systolic blood pressure <90 mmHg
Juntendo University
Lead sponsor
Boehringer Ingelheim
Collaborator